NORCROSS, Ga., Nov. 08, 2016 -- Immucor, Inc., a global leader in transfusion and transplantation diagnostics, today announced that its next-generation, fully automated Echo® instrument, Echo Lumena™, has been deemed to meet the essential requirements of all relevant European Medical Device Directives and is currently CE marked for use in Europe and other markets outside of the US to best match donor-patient blood. Echo Lumena is Immucor’s fifth generation immunohematology instrument and brings brilliant performance and clearer test results with a smaller footprint per throughput than any other fully automated instrument on the global market.
Echo Lumena is designed for the small to mid-volume laboratory segment and joins its fully automated, next generation “sister” instrument, NEO Iris™ (for larger volume testing settings), to offer a total standardized workflow solution for any laboratory. “Whether a lab conducts five type and screens or 500 per day, every lab shares a critical goal to accurately pinpoint the best possible blood match for anyone that needs it,” said Keith Chaitoff, Immucor’s Chief Marketing Officer and Vice President of International Commercial Operations. Adds Christie Otis, Senior Transfusion Franchise Director, “With Echo Lumena, and with our NEO Iris, Immucor continues to empower more diverse lab settings to safely accelerate blood-related patient care decisions and help increase positive outcomes for more people around the globe.”
Echo Lumena builds on Immucor’s heritage of leadership and proven Capture® technology, with more than 1,500 Echo instruments already enabling labs globally. New capabilities for the improved Echo Lumena system include:
- Accuracy - Enhanced reader module provides clearer, real-time results and easy on-screen verification. Hardware and software upgrades also power assay algorithm modifications that improve performance;
- Flexibility - More process and reagent controls represent best-in-class technology to maximize safety and security with increased specificity and sensitivity capabilities. Plus the ability to load STAT samples at all times;
- Performance - Improved software functionalities including an updated Microsoft Operating System with security updates, plus additional software translations to Turkish, Swedish and Polish are now available.
Built-in Integration for Data Management and Support
Echo Lumena and all Immucor transfusion solutions integrate with the company’s comprehensive data management software solution, ImmuLINK®, to aggregate all serology and molecular test results, generating a single report with a complete donor or patient testing history. Echo Lumena also includes a bi-directional interface with blud_directSM for 24/7 remote diagnostics and instrument support.
Echo Lumena is part of Immucor’s commitment to immunohematology automation. As an industry leader with over 2,500 instrument placements worldwide, Immucor’s innovative technologies provide high-quality, high-performance scalable solutions to meet the operational needs of blood banks, donor centers and labs, regardless of size or volume. Immucor’s total solution extends beyond instrumentation to include serology, molecular and platelet specialty products. Echo Lumena along with its sister instrument, NEO Iris, are both CE marked for use in Europe. Clinical trials for Echo Lumena are in progress in the United States.
Request a Demonstration
To schedule a demonstration of Echo Lumena, NEO Iris, or any Immucor solution, Immucor clients may contact their Blood Bank Business Manager. For more information about Immucor products or to learn the regulatory status of our products in your country, please contact your local Immucor representative at [email protected] or visit www.immucor.com.
About Immucor
Founded in 1982, Immucor is a global leader in transfusion and transplantation diagnostics that facilitate patient-donor compatibility. Our mission is to ensure that patients in need of blood, organs or stem cells get the right match that is safe, accessible and affordable. With the right match, we can transform a life together. For more information on Immucor, visit www.immucor.com.
Contact: Michele Howard - 770.441.2051


Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026
Washington Post Publisher Will Lewis Steps Down After Layoffs
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
Instagram Outage Disrupts Thousands of U.S. Users 



